Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone267-824-2827
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees17
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Madrigal Pharmaceuticals (NASDAQ:MDGL) Frequently Asked Questions
What is Madrigal Pharmaceuticals' stock symbol?
Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."
How were Madrigal Pharmaceuticals' earnings last quarter?
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) issued its earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.22) by $0.06. During the same period last year, the firm earned ($0.45) earnings per share. View Madrigal Pharmaceuticals' Earnings History.
When is Madrigal Pharmaceuticals' next earnings date?
What price target have analysts set for MDGL?
12 equities research analysts have issued 12-month target prices for Madrigal Pharmaceuticals' shares. Their predictions range from $126.00 to $250.00. On average, they anticipate Madrigal Pharmaceuticals' stock price to reach $177.00 in the next year. This suggests a possible upside of 76.6% from the stock's current price. View Analyst Price Targets for Madrigal Pharmaceuticals.
What is the consensus analysts' recommendation for Madrigal Pharmaceuticals?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Madrigal Pharmaceuticals.
What are Wall Street analysts saying about Madrigal Pharmaceuticals stock?
Here are some recent quotes from research analysts about Madrigal Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-ß agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-ß agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania. " (8/27/2019)
- 2. HC Wainwright analysts commented, "We are confident that the MAESTRO-NASH trial is well-managed: it is conducted by PRA Health Sciences (private), a top CRO that was awarded the 2019 CRO a top drawer group of clinical site investigators including principal investigator Dr. Antonio, TX. Importantly, MAESTRO-NASH’s 52-week treatment period was selected in order to optimize patient compliance and the repeat biopsy rate, as both drop off considerably in trials that last more than one year." (7/3/2019)
- 3. Stifel Nicolaus analysts commented, "We believe resmetirom’s Phase 2b data are encouraging on NASH resolution and emerging evidence continues to point to the possibility resmetirom could demonstrate a benefit on fibrosis over time. We are positively biased heading into Phase 3 however; we see few company specific catalysts to drive shares upward in the next ~12-18 months and think the stock could be volatile around updates from competitors (i.e. VKTX, GNFT, etc.) – this leads to our Hold rating. Ultimately, we feel MDGL will largely remain range bound before it reports Phase 3, 52-week data in 2H21 and based on our diligence for our NASH white paper (link here), we suspect any strategic acquirer would want to confirm resmetirom’s safety/efficacy profile and gain some commercial validation for the NASH category, as a whole, before paying a large price tag for MDGL. So a near-term takeout is unlikely, in our view." (6/24/2019)
Has Madrigal Pharmaceuticals been receiving favorable news coverage?
News headlines about MDGL stock have been trending negative this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Madrigal Pharmaceuticals earned a news impact score of -2.9 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Madrigal Pharmaceuticals.
Who are some of Madrigal Pharmaceuticals' key competitors?
Some companies that are related to Madrigal Pharmaceuticals include ACADIA Pharmaceuticals (ACAD), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), The Medicines (MDCO), Allakos (ALLK), United Therapeutics (UTHR), FibroGen (FGEN), Alkermes (ALKS), Nektar Therapeutics (NKTR), Evotec (EVTCY), Mirati Therapeutics (MRTX), Taro Pharmaceutical Industries (TARO) and Global Blood Therapeutics (GBT).
What other stocks do shareholders of Madrigal Pharmaceuticals own?
Who are Madrigal Pharmaceuticals' key executives?
Madrigal Pharmaceuticals' management team includes the folowing people:
- Dr. Paul A. Friedman, Chairman & CEO (Age 76)
- Dr. Rebecca A. Taub, Founder, Exec. VP of R&D, Chief Medical Officer and Director (Age 67)
- Mr. Marc R. Schneebaum, Sr. VP & CFO (Age 65)
- Mr. Thomas W. Hare, Sr. VP of Clinical Management
Who are Madrigal Pharmaceuticals' major shareholders?
Madrigal Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.87%), BlackRock Inc. (3.64%), Jennison Associates LLC (1.98%), Jennison Associates LLC (1.98%), Rock Springs Capital Management LP (1.67%) and Price T Rowe Associates Inc. MD (1.50%). Company insiders that own Madrigal Pharmaceuticals stock include Bay City Capital Llc, Fred B Craves, Marc R Schneebaum, Paul A Friedman and Rebecca Taub. View Institutional Ownership Trends for Madrigal Pharmaceuticals.
Which major investors are selling Madrigal Pharmaceuticals stock?
MDGL stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Vanguard Group Inc., JPMorgan Chase & Co., Bank of America Corp DE, Jennison Associates LLC, Jennison Associates LLC, Alps Advisors Inc. and Bank of Montreal Can. View Insider Buying and Selling for Madrigal Pharmaceuticals.
Which major investors are buying Madrigal Pharmaceuticals stock?
MDGL stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., BlackRock Inc., Point72 Asset Management L.P., Nuveen Asset Management LLC, Nomura Holdings Inc., Nomura Holdings Inc., University of Notre Dame DU Lac and Russell Investments Group Ltd.. Company insiders that have bought Madrigal Pharmaceuticals stock in the last two years include Fred B Craves and Paul A Friedman. View Insider Buying and Selling for Madrigal Pharmaceuticals.
How do I buy shares of Madrigal Pharmaceuticals?
Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Madrigal Pharmaceuticals' stock price today?
One share of MDGL stock can currently be purchased for approximately $100.24.
How big of a company is Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals has a market capitalization of $1.55 billion. The biopharmaceutical company earns $-32,810,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis. Madrigal Pharmaceuticals employs 17 workers across the globe.View Additional Information About Madrigal Pharmaceuticals.
What is Madrigal Pharmaceuticals' official website?
How can I contact Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at 267-824-2827 or via email at [email protected]
MarketBeat Community Rating for Madrigal Pharmaceuticals (NASDAQ MDGL)
MarketBeat's community ratings are surveys of what our community members think about Madrigal Pharmaceuticals and other stocks. Vote "Outperform" if you believe MDGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDGL will underperform the S&P 500 over the long term. You may vote once every thirty days.
